Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sh-PMEL refers to a **short hairpin RNA (shRNA) targeting the PMEL gene**, which encodes premelanosome protein, also known as glycoprotein 100 or gp100. PMEL is a pigment cell-specific transmembrane glycoprotein essential for melanosome structure and function and is implicated as a tumor antigen in melanoma. RNA interference through shRNA targeting PMEL would be utilized to regulate, knock down, or silence PMEL expression, typically in research or investigational contexts such as cancer immunotherapy or studies of melanosome biology[1][2][7]. Such RNA-based therapeutics could potentially suppress pigment cell function, affect pigmentation, or modulate immune targeting in melanoma models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sh-PMEL.